Abstract
Disposition decomposition analysis (DDA) is applied to evaluate the rate and extent of drug delivery from the sampling compartment to the peripheral system, i.e., peripheral bioavailability. Four parameters are introduced which are useful in quantifying peripheral bioavailability. The compounded peripheral bioavailability, Fcomp,is the ratio between the total compounded amount of drug transferred to the peripheral system and the injected dose, D.The AUCperipheral bioavailability, FAUC,is the ratio between the area under the amount vs.time curves for the peripheral system and the sampling compartment. The distribution time td,is the time following an i.v. bolus at which the net transfer of drug to the peripheral system reverses in direction. The maximum peripheral bioavailability, Fmax,is the maximum fraction of an i.v. bolus dose that is present in the peripheral system at any one time. Equations are derived which permit estimation of those parameters from drug concentrations in the sampling compartment. Simple algorithms and a computer program are provided for estimating Fcomp, FAUC, td, Fmax,and other parameters relevant to DDA for drugs that exhibit a linear polyexponential bolus response. Estimates of Ecomp, FAUC, td,are presented for several drugs.
Similar content being viewed by others
References
J. G. Wagner.Fundamentals of Clinical Pharmacokinetics, 1st ed., Drug Intelligence Publications, Hamilton, IL, 1975, pp. 337–342.
V. F. Smolen and R. D. Schoenwald. Drug absorption analysis from pharmacological data I: Method and confirmation exemplified for the mydriatic drug tropicamide.J. Pharm. Sci. 60:96–103 (1971).
V. F. Smolen and W. A. Weigand. Drug bioavailability and pharmacokinetic analysis from pharmacological data.J. Pharmacokin. Biopharm. 1:329–336 (1973).
V. F. Smolen. Theoretical and computational basis for drug bioavailability determinations using pharmacological data. I. General considerations and procedures.J. Pharmacokin. Biopharm. 4:337–353 (1976).
W. R. Gillespie and P. Veng-Pedersen. Theorems and implications of a model independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. II. Clearance concepts applied to the evaluation of distribution kinetics.J. Pharmacokin. Biopharm. 13:441–451 (1985).
P. Veng-Pedersen and W. R. Gillespie. The mean residence time in peripheral tissue. A linear disposition parameter useful for evaluating drug's tissue distribution.J. Pharmacokin. Biopharm. 12:535–543 (1984).
P. Veng-Pedersen and W. R. Gillespie. The mean residence time of drugs in the systemic circulation.J. Pharm. Sci. 74:791–792 (1985).
P. Veng-Pedersen. Theorems and implications of a model independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. I. Derivations and theoretical analysis.J. Pharmacokin. Biopharm. 12:627–648 (1984).
C. D. Thron. Linearity and superposition in pharmacokinetics.Pharmacol. Rev. 26:3–31 (1974).
G. B. Park, R. P. Kershner, J. Angellotti, R. L. Williams, L. Z. Benet, and J. Edelson, Oral bioavailability and intravenous pharmacokinetics of amrinone in humans.J. Pharm. Sci. 72:817–819 (1983).
M. Rowland and S. Riegelman. Pharmacokinetics of acetylsalicylic acid and salicylic acid after intravenous administration in man.J. Pharm. Sci. 57:1313–1319 (1968).
P. K. Narang, J. Adir, J. Josselson, A. Yacobi, and J. Sadler. Pharmacokinetics of bretylium in man after intravenous administration.J. Pharmacokin. Biopharm. 8:363–372 (1980).
P. J. PentikÄinen, P. J. Neuvonen, M. Kekki, and A. PenttilÄ. Pharmacokinetics of intravenously administered bumetanide in man.J. Pharmacokin. Biopharm. 8:219–228 (1980).
N. S. Aziz, J. G. Gambertoglio, E. T. Lin, H. Grausz, and L. Z. Benet. Pharmacokinetics of cefamandole using a HPLC assay.J. Pharmacokin. Biopharm. 6:153–164 (1978).
A. Gerardin, J. B. Lecaillon, J. P. Schoeller, G. Humbert, and J. Guibert. Pharmacokinetics of cefroxadin (CGP9000) in man.J. Pharmacokin. Biopharm. 10:15–26 (1982).
J. T. Burke, W. A. Wargin, R. J. Sherertz, K. L. Sanders, M. R. Blum, and F. A. Sarubbi. Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function.J. Pharmacokin. Biopharm. 10:601–614 (1982).
H. G. Boxenbaum, K. A. Geitner, M. L. Jack, W. R. Dixon, H. E. Spiegel, J. Symington, R. Christian, J. D. Moore, L. Wiessman, and S. A. Kaplan. Pharmacokinetic and biopharmaceutic profile of chlordiazepoxide-HCl in healthy subjects: Single-dose studies by the intravenous, intramuscular, and oral routes.J. Pharmacokin. Biopharm. 5:3–23 (1977).
S. E. Tsuei, R. G. Moore, J. J. Ashley, and W. G. McBride. Disposition of synthetic glucocorticoids. I. Pharmacokinetics of dexamethasone in healthy adults.J. Pharmacokin. Biopharm. 7:249–264 (1979).
S. A. Kaplan, M. L. Jack, K. Alexander, and R. E. Weinfeld. Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations.J. Pharm. Sci. 62:1789–1796 (1973).
A. W. Kelman and B. Whiting. Modeling of drug response in individual subjects.J. Pharmacokin. Biopharm. 8:115–130 (1980).
J. R. Koup, D. J. Greenblatt, W. J. Jusko, T. W. Smith, and J. R. Koch-Weser. Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses.J. Pharmacokin. Biopharm. 3:181–192 (1975).
P. G. Welling and W. A. Craig. Pharmacokinetics of intravenous erythromycin.J. Pharm. Sci. 67:1057–1059 (1978).
C. S. Lee, D. C. Brater, J. G. Gambertoglio, and L. Z. Benet. Disposition kinetics of ethambutol in man.J. Pharmacokin. Biopharm. 8:335–346 (1980).
P. H. Hinderling, U. Gundert-Remy, D. Förster, and W. Gau. The pharmacokinetics of furazlocillin in healthy humans.J. Pharmacokin. Biopharm. 11:5–30 (1983).
P. Chennavasin, R. A. Johnson, and D. C. Brater. Variability in derived parameters of furosemide pharmacokinetics.J. Pharmacokin. Biopharm. 9:623–633 (1981).
M. Rowland, S. Riegelman, and W. L. Epstein. Absorption kinetics of griseofulvin in man.J. Pharm. Sci. 57:984–989 (1968).
R. Platzer, G. Reutemann, and R. L. Galeazzi. Pharmacokinetics of intravenous isosorbide dinitrate.J. Pharmacokin. Biopharm. 10:575–586 (1982).
D. J. Greenblatt, R. I. Shader, K. Franke, D. S. MacLaughlin, J. S. Harmatz, M. D. Allen, A. Werner, and E. Woo. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans.J. Pharm. Sci. 68:57–63 (1979).
D. J. Greenblatt, M. Divoll, J. S. Harmatz, and R. I. Shader. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam.J. Pharm. Sci. 71:248–252 (1982).
M. R. Dobrinska, W. Kukovetz, E. Beubler, H. Lorraine Leidy, H. J. Gomez, J. Demetriades, and J. A. Bolognese. Pharmacokinetics of the pivaloyloxyethyl (POE) ester of methyldopa, a new prodrug of methyldopa.J. Pharmacokin. Biopharm. 10:587–600 (1982).
R. Jochemsen, J. J. H. Hogendoorn, J. Dingemanse, J. Hermans, J. K. Boeijinga, and D. D. Breimer. Pharmacokinetics and bioavailability of intravenous, oral, and rectal nitrazepam in humans.J. Pharmacokin. Biopharm. 10:231–245 (1982).
J. W. Ward, A. McBurney, P. R. Farrow, and P. Sharp. Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.Eur. J. Clin. Pharmacol. 26:603–608 (1984).
C. V. Manion, D. Lalka, D. T. Baer, and M. B. Meyer. Absorption kinetics of procainamide in humans.J. Pharm. Sci. 66:981–984 (1977).
R. Gomeni, G. Bianchetti, R. Sega, and P. L. Morselli. Pharmacokinetics of propanolol in normal healthy volunteers.J. Pharmacokin. Biopharm. 5:183–192 (1977).
T. W. Guentert, N. H. G. Holford, P. E. Coates, R. A. Upton, and S. Riegelman. Quinidine pharmacokinetics in man: Choice of a disposition model and absolute bioavailability studies.J. Pharmacokin. Biopharm. 7:315–330 (1979).
A. Rakhit, N. H. G. Holford, T. W. Guentert, K. Maloney, and S. Riegelman. Pharmacokinetics of quinidine and three of its metabolites in man.J. Pharmacokin. Biopharm. 12:1–21 (1984).
P. A. Meredith, A. W. Kelman, H. L. Elliott, and J. L. Reid. Pharmacokinetic and pharmacodynamic modelling of trimazosin and its major metabolite.J. Pharmacokin. Biopharm. 11:323–335 (1983).
R. P. Brent.Algorithms for minimization without derivatives, Prentice-Hall, Englewood Cliffs, NJ, 1973, chap. 4.
G. E. Forsythe, M. A. Malcolm, and C. B. Moler.Computer methods for mathematical computations, Prentice-Hall, Englewood Cliffs, NJ, 1977, pp. 161–166.
W. R. Gillespie and P. Veng-Pedersen. The determination of mean residence time using statistical moments:It is correct.J. Pharmacokin. Biopharm. 13:549–554 (1985).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Veng-Pedersen, P., Gillespie, W.R. Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailahility and distribution time concepts applied to the evaluation of distribution kinetics. Journal of Pharmacokinetics and Biopharmaceutics 15, 281–304 (1987). https://doi.org/10.1007/BF01066323
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01066323